Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418017 | 1.00 | CA1 (0.39) | CA1CA2CA4CA9POLB | |
| SCHEMBL1710377 | 1.00 | CA1 (0.39) | CA1CA2CA4CA9POLB | |
| Hydrochloric Acid SCHEMBL26117076 | 0.98 | CA1 (0.38) | CA1CA2CA4CA9POLB | |
| Hydrochloric Acid SCHEMBL26117071 | 0.98 | CA1 (0.38) | CA1CA2CA4CA9POLB | |
| SCHEMBL2419861 | 0.85 | CA1 (0.52) | CA1CA2CA4CA9SLC6A1 | |
| SCHEMBL3494643 | 0.85 | CA1 (0.52) | CA1CA2CA4CA9SLC6A1 | |
| SCHEMBL18705695 | 0.85 | CA1 (0.52) | CA1CA2CA4CA9SLC6A1 | |
| Piperazine SCHEMBL2231464 | 0.84 | CA1 (0.34) | CA1CA2CA4CA9CHRNB2 | |
| SCHEMBL23182198 | 0.83 | CA1 (0.38) | CA1CA2CA4CA9POLB | |
| SCHEMBL28766525 | 0.83 | DPP4 (0.38) | CA1CA2CA4CA9SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| EP-4676547-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024186584-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024124287-A1 | COMPOUNDS FOR TREATING VIRAL INFECTION | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| CN-101305011-A | Pyridine derivatives and their use in the treatment of psychotic disorders | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | CN | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CA1 1965/4885CA2 81/4885CA4 295/4885 |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | CA1 1912/4885CA2 170/4885CA4 1978/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | CA1 2973/4885CA2 2281/4885CA4 3593/4885 |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | CA1 4171/4885CA2 3352/4885CA4 2883/4885 |
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | CA1 4699/4885CA2 4652/4885CA4 4641/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | CA1 3485/4885CA2 1843/4885CA4 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.